Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Net Margin (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Net Margin data on record, last reported at 101.83% in Q4 2025.

  • For Q4 2025, Net Margin fell 8474.0% year-over-year to 101.83%; the TTM value through Dec 2025 reached 12.18%, up 1315.0%, while the annual FY2025 figure was 12.18%, 1315.0% up from the prior year.
  • Net Margin reached 101.83% in Q4 2025 per APLS's latest filing, down from 47.04% in the prior quarter.
  • Across five years, Net Margin topped out at 1776.89% in Q4 2022 and bottomed at 35183.15% in Q2 2021.
  • Average Net Margin over 5 years is 2110.7%, with a median of 55.29% recorded in 2025.
  • Peak YoY movement for Net Margin: skyrocketed 3422744bps in 2022, then tumbled -180427bps in 2023.
  • A 5-year view of Net Margin shows it stood at 470.05% in 2021, then skyrocketed by 278bps to 1776.89% in 2022, then tumbled by -102bps to 27.38% in 2023, then soared by 38bps to 17.09% in 2024, then crashed by -496bps to 101.83% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 101.83% in Q4 2025, 47.04% in Q3 2025, and 23.61% in Q2 2025.